Addition of Diagnostic Products, Research Data, Patents and Technology Complements Cardisio’s Platform for AI-Based Heart Health

Frankfurt, Germany, January 31., 2022—Cardisio GmbH, developer of the world’s first non-invasive, highly accurate screening method for heart diseases, today announced the acquisition of the assets of Enverdis GmbH, an innovator in cardiovascular functional diagnosis. With this acquisition, Cardisio deepens its technology, research data and product portfolio in the market for AI-based heart health.

Read here for more information.